If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

4 Jan 2024 17:30

Arix Bioscience PLC (ARIX) Holding(s) in Company 04-Jan-2024 / 17:30 GMT/BST


TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

ARIX Bioscience PLC

 

1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an “X”)

An acquisition or disposal of voting rights

 

An acquisition or disposal of financial instruments

X

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Weiss Asset Management LP

City and country of registered office (if applicable)

Wilmington, Delaware, USA

4. Full name of shareholder(s) (if different from 3.)v

Name

Brookdale International Partners, L.P., Brookdale Global Opportunity Fund

City and country of registered office (if applicable)

Brookdale International Partners, L.P.: Albany, NY, USA

Brookdale Global Opportunity Fund: Grand Cayman, Cayman Islands

5. Date on which the threshold was crossed or reachedvi:

January-2-2024

6. Date on which issuer notified (DD/MM/YYYY):

January-4-2024

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

0.00

5.19

5.19

129,389,508

Position of previous notification (if

applicable)

 

N/A

 

N/A

 

N/A

 

             

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

 

 

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/ Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/ Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

CFD

N/A

N/A

Cash Settlement

6,725,000

5.19

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

6,725,000

5.19

 

                   

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an “X”)

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Weiss Asset Management LP

 

 

 

Brookdale International Partners, L.P.

0.00

2.90

2.90

 

 

 

 

Weiss Asset Management LP

 

 

 

Brookdale Global Opportunity Fund

0.00

2.29

2.29

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

Weiss Asset Management LP is the Investment Manager to Brookdale Global Opportunity Fund and Brookdale International Partners, L.P.

         

 

Place of completion

Boston, USA

Date of completion

January-4-2024

 


Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
ISIN:GB00BD045071
Category Code:HOL
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 2.3. Major shareholding notifications
Sequence No.:295596
EQS News ID:1808641
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
1st Oct 20202:40 pmEQSLogicBio announces pricing of public offering
21st Sep 202011:20 amEQSHardman & Co Research: Arix Bioscience (ARIX): Realising the valuation disconnect
18th Sep 20208:57 amEQSArix Bioscience PLC: Autolus presents additional AUTO3 data in DLBCL
8th Sep 20207:00 amEQSArix Bioscience PLC: Interim Results for the Six Months Ended 30 June 2020
13th Aug 20207:07 amPRNNotice of Results
10th Aug 202012:49 pmPRNLogicBio announces IND clearance for LB-001
31st Jul 20202:06 pmRNSSecond Price Monitoring Extn
31st Jul 20202:00 pmRNSPrice Monitoring Extension
31st Jul 20207:01 amPRNTotal Voting Rights
20th Jul 20201:28 pmPRNAmplyx announces positive Phase 2 data
10th Jul 20207:53 amPRNAtox Bio plans NDA submission for Q3 2020
8th Jul 20201:27 pmPRNVelosBio completes $137 million Series B financing
1st Jul 20207:00 amPRNDirector/PDMR Shareholding, Issue of Ordinary Shares
1st Jul 20207:00 amPRNDirector/PDMR Shareholding, Issue of Ordinary Shares
12th Jun 20202:24 pmPRNAura presents updated AU-011 clinical data at ARVO 2020
12th Jun 20201:34 pmPRNImara presents positive interim Phase 2a data at EHA
12th Jun 20209:13 amPRNAutolus AUTO1 and AUTO3 data at EHA
8th Jun 20207:08 amPRNArix announces strategic and operational update
4th Jun 20205:42 pmPRNResults of Annual General Meeting
1st Jun 20202:57 pmPRNIterum announces topline Phase 3 data in complicated UTI
29th May 20201:38 pmPRNHarpoon presents interim Phase 1 data for HPN424
29th May 20201:06 pmPRNAutolus presents additional AUTO3 data in DLBCL
27th May 20204:40 pmRNSSecond Price Monitoring Extn
27th May 20204:35 pmRNSPrice Monitoring Extension
20th May 20207:00 amPRNAmplyx closes $53 million Series C extension
19th May 20209:35 amEQSHardman & Co Research: Arix Bioscience (ARIX): 1Q'20 portfolio update
12th May 20207:00 amPRNNotice of Annual General Meeting
28th Apr 20209:23 amPRNPharmaxis announces new data in myelofibrosis
27th Apr 20201:12 pmPRNHarpoon doses first patient in multiple myeloma trial
23rd Apr 20207:30 amEQSHardman & Co Research: Arix Bioscience (ARIX): Resetting the stage
17th Apr 20202:59 pmPRNDirector/PDMR Shareholding
16th Apr 20201:08 pmPRNAutolus announces FDA acceptance of IND application
6th Apr 20207:00 amPRNChanges to Board of Directors and executive leadership
19th Mar 202010:31 amEQSHardman & Co Research: Arix Bioscience (ARIX): Fiscal 2019 - moving with the times
16th Mar 20207:00 amPRNDirector/PDMR Shareholding
12th Mar 20207:11 amPRNImara prices Nasdaq IPO
10th Mar 20207:00 amPRNAnnual Results for the year ended 31 December 2019
9th Mar 202012:00 pmPRNDr Roberto Iacone appointed as EiR
3rd Mar 202012:18 pmPRNUpdate on Imara proposed IPO in the United States
3rd Mar 20207:30 amEQSHardman & Co Research: Q&A with Q&A with Dr Dorothea Hill on Arix Bioscience (ARIX)
27th Feb 202012:00 pmPRNNotice of Results
24th Feb 20201:26 pmPRNAura announces updated Phase 1b/2 clinical data
19th Feb 20207:30 amEQSHardman & Co Research: Arix Bioscience (ARIX) - Initiation of coverage: With high risk can come high reward
17th Feb 20207:00 amPRNImara files for proposed IPO in the United States
30th Jan 202012:08 pmPRNAutolus presents encouraging additional AUTO3 data
27th Jan 20207:00 amPRNArix co-founds Quench Bio with Series A financing
23rd Jan 20207:00 amPRNAutolus announces pricing of public offering
17th Jan 20201:15 pmPRNIterum announces $52 million private placement
18th Dec 201910:00 amPRNPharmaxis business update
17th Dec 201910:57 amPRNBoard changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.